InvestorsHub Logo
Post# of 252302
Next 10
Followers 120
Posts 20670
Boards Moderated 0
Alias Born 06/13/2011

Re: DewDiligence post# 226080

Tuesday, 09/03/2019 3:58:04 PM

Tuesday, September 03, 2019 3:58:04 PM

Post# of 252302
Dew re ARDX ...thx for posting that note

All the dialysis patients my wife ( Renal PA ) treats are on phosphate binders and its a real struggle for them
So these results are important and especially the results of the mono therapy due in last qt
From the PR

"I believe tenapanor has the potential to change the landscape of hyperphosphatemia treatment – finally, a novel agent that can lower serum phosphorus alone or in conjunction with binders," said Glenn Chertow, M.D., M.P.H., division chief of nephrology and professor of medicine at Stanford University.
"Faced with an extremely high mortality rate of approximately 18% per year in dialysis patients, we are very focused on managing and treating elevated serum phosphorus.
Elevated serum phosphorus is associated with mortality, cardiovascular events and bone fracture among patients receiving dialysis, and more than half of patients cannot achieve control of hyperphosphatemia despite taking a fist full of binders three times daily with meals... (.my emphasis )
The AMPLIFY study results provide convincing evidence that controlling hyperphosphatemia will soon be within our reach."

------------------
Kiwi.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.